Evaxion A/S American Depositary Share (EVAX)
Evaxion A/S American Depositary Share (EVAX) is listed on Nasdaq, where it has traded since February 5, 2021.
- Listed On
- Nasdaq
- Listed Since
- February 5, 2021
- Employees
- 46
- Market Cap
- $30M
About Evaxion A/S American Depositary Share
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 20 institutions reported holding EVAX, with 1.6 million shares worth $4.9 million in aggregate. The largest reported holder was Merck & Co, with 1.2 million shares worth $3.8 million. Of the 5 largest holders listed below, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Merck & Co | 1,214,126 | $4M | Unchanged |
| Ikarian Capital | 74,698 | $232K | Unchanged |
| Rathbones Group | 45,723 | $142K | Unchanged |
| Citadel Advisors | 36,584 | $113K | Added 105.84% |
| Renaissance Technologies | 33,800 | $105K | Reduced 13.83% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is EVAX?
Evaxion A/S American Depositary Share (EVAX) is listed on Nasdaq, where it has traded since February 5, 2021.
Who are the largest institutional holders of EVAX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of EVAX were Merck & Co, Ikarian Capital and Rathbones Group.
How many institutions own EVAX?
20 institutions reported a position in EVAX for the quarter ended June 30, 2026, worth $4.9 million in total.
Did institutions buy or sell EVAX last quarter?
Of the 5 largest reported holders, 1 added shares, 1 reduced its position and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for EVAX.
Every reported institutional holder, plus insider and congressional trades in EVAX, on SentiSense.